|Bid||0.0100 x 125665700|
|Ask||0.0110 x 8008500|
|Day's range||0.0100 - 0.0100|
|52-week range||0.0070 - 0.0250|
|Beta (5Y monthly)||1.22|
|PE ratio (TTM)||N/A|
|Earnings date||28 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||0.04|
MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a European based bio-pharma company specializing in the development and supply of affordable, ethically produced plant-inspired medicines, announces that its innovative product ArtemiC™ has recently been listed as an over-the-counter (OTC) drug in the USA on the FDA National Drug Code (NDC) Database under the code 83278. Facilitated by the company's US-based supply and distribution partner, AMCPharma USA, LLC. (AMC), ArtemiC™ will be
MGC Pharmaceuticals ( ASX:MXC ) First Half 2023 Results Key Financial Results Revenue: AU$2.66m (up 3.8% from 1H 2022...
MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), is a European based bio-pharma company, focused on developing and supplying affordable (Accessible) and Ethically Produced Plant Inspired Medicines, is helping to solve the mystery of treating Long COVID patients with a new herbal inspired medicine.